TOKYO, Dec 12, 2024 - (JCN Newswire) - - NEC Bio Therapeutics today presents 24-week promising interim results from an ongoing Phase 1 basket clinical trial of an orally administered cancer vaccine, ...
NEC Bio Therapeutics, a company focuses on the clinical strategy and development, as well as planning and execution of clinical trials in the oncology area, presents 24-week promising interim results ...
Interim results from an ongoing clinical trial of NECVAX-NEO1 highlight its safety and immunogenicity. These results are NEC's first proof-of-concept for an investigational oral DNA vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results